Telomere length, molecular cytogenetic findings, and immunophenotypic features in previously untreated patients with B-chronic lymphocytic leukemia

Neoplasma

Volumn 57, Issue 3, 2010, Pages 215-221

  Brezinova, J ^a   Berkova, A ^b   Vcelikova, S ^a   Zemanova, Z ^b   Izakova, S ^a   Sarova, I ^a   Cechova, H ^a   Tajtlova, J ^b   Grosova, L ^b   Lizcova, L ^b   Malinova, E ^b   Zemanova, M ^b   Cmunt, E ^b   Karban, J ^b   Trneny, M ^b   Schwarz, J ^a   Michalova, K ^a,b  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

B chronic lymphocytic leukemia; Chromosomal aberrations; Prognosis; Telomerase activity; Telomere length

Indexed keywords

CD38 ANTIGEN; PROTEIN KINASE ZAP 70; TELOMERASE; IMMUNOGLOBULIN HEAVY CHAIN; ZAP70 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CANCER PROGNOSIS; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MALE; MUTATION; PROTEIN EXPRESSION; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; TELOMERE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; TELOMERE; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 77954635846     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2010_03_215     Document Type: Article

References (30)

1. RAI KR, SAWITZKI A, CRONKITE EP, CHANANA AD, LEVY RN et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46:219-34.
2. BINET JL, LEPORRIER M, DIGHIERO G, CHARRON D, D'ATHIS P et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977; 40: 855-64. doi:10.1002/1097-0142(197708)40:2<855::AIDCNCR2820400239> 3.0.CO;2-1
3. DÖHNER H, STILGENBAUER S, BENNER A, LEUPOLT E, KRÖBER A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-6. doi:10.1056/NEJM200012283432602
4. DICKER F, SCHNITTGER S, HAFERLACH T, KERN W, SCHOCH C. Imunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006; 108: 3152-60. doi:10.1182/blood-2006-02-005322
5. HAFERLACH C, DICKER F, SCHNITTGER S, KERN W, HAFERLACH T. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interhase FISH, IgV(H) status and immunophenotyping. Leukemia 2007; 21: 2442-51. doi:10.1038/sj.leu.2404935
6. OSCIER DG, GARDINER AC, MOULD SJ, GLIDE S, DAVIS ZA et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177-84.
7. HAMBLIN TJ, DAVIS Z, GARDINER A, OSCIER DG, STEVENSON FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-54.
8. DAMLE RN, WASIL T, FAIS F, GHIOTTO F, VALETTO A et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-7.
9. VAN BOCKSTAELE F, VERHASSELT B, PHILIPPÉ J. Prognostic markers in chronic lymphocytic leukemia: a comprehenshive review. Blood Rev 2009; 23: 25-47. doi:10.1016/j.blre.2008.05.003
10. HAMBLIN TJ, ORCHARD JA, IBBOTSON RE, DAVIS Z, THOMAS PW et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99: 1023-29. doi:10.1182/blood.V99.3.1023
11. HAYAT A, O'BRIEN D, O'ROURKE P, MCGUCKIN S, FITZGERALD T et al. CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia. Leuk Lymphoma 2006; 47: 2371-9. doi:10.1080/10428190600947727
12. WIESTNER A, ROSENWALD A, BARRY TS, WRIGHT G, DAVIS RE et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944-51. doi:10.1182/blood-2002-10-3306
13. BLACKBURN EH. Switching and signaling at the telomere. Cell 2001; 106: 661-73. doi:10.1016/S0092-8674(01)00492-5
14. IWAMA H, OHYASHIKI K. OHYASHIKI JH, HAYASHI S, YAHATA N et al. Telomeric length and telomerase activity vary with age in peripheral blood cells obtained from normal individuals. Hum Genet 1998; 102: 397-402. doi:10.1007/ s004390050711
15. PEKOVÁ S, MARKOVÁ J, PAJER P, DVORÁK M, CETKOVSKÝ P et al. Touch-down reverse transcriptase-PCR detection of IgV(H) rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia. Mol Diagn 2005; 9: 23-34. doi:10.2165/00066982-200509010-00004
16. SCHWARZ J, MIKULENKOVÁ D, CERMÁKOVÁ K, POLANSKÁ V, MICHALOVÁ K et al. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers. Neoplasma 2006; 53: 219-25.
17. ŠINDELÁŘOVÁ L, MICHALOVÁ K, ZEMANOVÁ Z, RANSDORFOVÁ S, BREZINOVÁ J et al. Incidence of chromosomal anomalies detected with FISH and their clinical correlations in B-chronic lymphocytic leukemia. Cancer Genet Cytogenet 2005; 160: 27-34. doi:10.1016/j.cancergen cyto.2004.11.004
18. GRABOWSKI P, HULTDIN M, KARLSSON K, TOBIN G, ALESKOG A et al. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood 2005; 105: 4807-12. doi:10.1182/ blood-2004-11-4394
19. RICCA I, ROCCI A, DRANDI D, FRANCESE R, COMPAGNO M et al. Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. Leukemia 2007; 21: 697-705.
20. BERKOVA A, PAVLISTOVA L, BABICKA L, HOUSKOVA L, TAJTLOVA J et al. Combined molecular biological and molecular cytogenetic analysis of genomic changes in 146 patients with B-cell chronic lymphocytic leukemia. Neoplasma 2008; 55: 400-8.
21. WU KD, ORME LM, SHAUGHNESSY J JR, JACOBSON J, BARLOGIE B et al. Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood 2003; 101: 4982-9. doi:10.1182/blood-2002-11-3451
22. SWIGGERS SJ, KUIJPERS MA, DE CORT MJ, BEVERLOO HB, ZIJLMANS JM. Critically short telomeres in acute myeloid leukemia with loss or gain of parts of chromosomes. Genes Chromosomes Cancer 2006; 45: 247-56. doi:10.1002/gcc.20286
23. SIEGLOVÁ Z, ŽILOVCOVÁ S, ČERMÁK J, ŘÍHOVÁ H, BŘEZINOVÁ D et al. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis? Leuk Res 2004; 28: 1013-21. doi:10.1016/j.leukres.2003.11.020
24. ROOS G, KRÖBER A, GRABOWSKI P, KIENLE D, BÜHLER A et al. Short telomeres are associated with genetic complexity, high risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood 2008; 111: 2246-52. doi:10.1182/blood-2007-05-092759
25. SHAY JW, BACCHETTI S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787-91. doi:10.1016/ S0959-8049(97)00062-2
26. VERSTOVSEK S, GILES FJ, O'BRIEN S, FADERL S, KANTARJIAN HM et al. Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia. Leuk Res 2004; 28: 707-11. doi:10.1016/j.leukres.2003.11.009
27. TRENTIN L, BALLON G, OMETTO L, PERIN A, BASSO U et al. Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. Br J Haematol 1999; 106: 662-8. doi:10.1046/j.1365-2141.1999.01620.x
28. DAMLE RN, BATLIWALLA FM, GHIOTTO F, VALETTO A, ALBESIANO E et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood 2004; 103: 375-82. doi:10.1182/blood-2003-04-1345
29. TERRIN L, TRENTIN L, DEGAN M, CORRADINI I, BERTORELLE R, et al. Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome. Leukemia 2007; 21: 965-72.
30. BINET JL, CALIGARIS-CAPPIO F, CATOVSKY D, CHESON B, DAVIS T et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006; 107: 859-61. doi:10.1182/blood-2005-04-1677